13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • CA209-650

    Acronym: 

    Checkmate 650

    ACTRN/NCT /ethics: 

    NCT02985957

    Scientific title: 

    Study of Nivolumab Plus Ipilimumab, Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer

    Summary of trial and patient characteristics

    Cancer Type Prostate
    Trial Type Treatment
    Phase Phase II Tumour Stream Prostate cancer
    Age Range 18 years and older Cancer Stage Metastatic or Widespread
    Sex Male Anticipated Start Date 2017-03-17
    Molecular Target Anticipated End Date 2022-05-30
    Cancer Type Prostate
    Trial Type Treatment
    Phase Phase II
    Age Range 18 years and older
    Sex Male
    Molecular Target
    Tumour Stream Prostate cancer
    Cancer Stage Metastatic or Widespread
    Anticipated Start Date 2017-03-17
    Anticipated End Date 2022-05-30

    Trial Summary

    A phase 2 trial of nivolumab plus ipilimumab, ipilimumab alone, or cabazitaxel in men with metastatic castration-resistant prostate cancer

    Lay Summary

    Study of Nivolumab Plus Ipilimumab, Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer

    Sponsor / Cooperative group

    Bristal-Myers Squibb

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Lyell McEwin Hospital Andy Phay andy.phay@sa.gov.au 08 8282 0833 Dr Christopher Hocking Recruiting